ACS Chemical Neuroscience · 2018 · 42 citations · 25 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryNeuropharmacologyBlood-brain Barrier PenetrationBlood-brain Barrier PharmacologyCholinergic PharmacologyDementia PharmacotherapyMulti-target Drug DesignNeurodegenerative Disease PharmacotherapyAntioxidant PharmacologyAntioxidant PropertiesDementia Drug DevelopmentDual-target InhibitorsMonoamine Oxidase InhibitionMonoamine Oxidase InhibitorsMonoamine OxidasesRational Design
Multifunctional agents aiming at cholinesterases (ChEs) and monoamine oxidases (MAOs) are promising therapy for Alzheimer’s disease (AD). Herein, a series of novel propargylamine-modified pyrimidinylthiourea derivatives (1–4) were designed and synthesized as dual inhibitors of ChEs and MAOs with other functions against AD. Most of these derivatives inhibited ChEs and MAOs with IC50 values in the micro- or nanomolar ranges. Compound 1c displayed the dual functional profile of targeting the AChE (IC50 = 0.032 ± 0.007 μM) and MAO-B (IC50 = 2.117 ± 0.061 μM), along with the improved blood-brain barrier (BBB) permeability, antioxidant ability, and good copper chelating property in vitro. Animal studies showed that compound 1c·HCl could inhibit the cerebral AChE/MAO-B activities and alleviate scopolamine-induced cognitive impairment in mice. Combined with good oral bioavailability (F = 45.55%), these findings demonstrated that compound 1c may be a potent brain permeable multifunctional candidate for the treatment of AD.
25
A new and rapid colorimetric determination of acetylcholinesterase activity
George L. Ellman, K. Diane Courtney, Valentino Andres et al. · Biochemical Pharmacology · 1961 · 26.9K citations